
The FDA has approved an expansion of the Phase III CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy) trial, which is evaluating the safety and efficacy of NeoVista's epiretinal brachytherapy in wet age-related macular degeneration (AMD).